| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/22/2007 | WO2007020190A1 Fluoro substituted 2-oxo azepan derivatives |
| 02/22/2007 | WO2007019933A1 1-acyldihydropyrazol derivatives |
| 02/22/2007 | WO2007019884A1 Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| 02/22/2007 | WO2007019678A1 Methods and devices for lymphatic targeting |
| 02/22/2007 | WO2006120474A3 Compositions for inducing an immune response against tumor antigens |
| 02/22/2007 | WO2006119402A3 C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth |
| 02/22/2007 | WO2006108681A3 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria |
| 02/22/2007 | WO2006108679A3 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer |
| 02/22/2007 | WO2006104911A3 Methods and compositions for modulating hyperstabilized c-met |
| 02/22/2007 | WO2006099169A3 Novel liposome compositions |
| 02/22/2007 | WO2006097617B1 Novel dihydropyrimidine derivatives and their use as anti-cancer agents |
| 02/22/2007 | WO2006091897A3 Derivatives of 8-substituted xanthines |
| 02/22/2007 | WO2006091896A3 Pyridyl substituted xanthines |
| 02/22/2007 | WO2006086638A3 Targeting lipocalin-2 for cancer therapeutics |
| 02/22/2007 | WO2006071441A3 Antibodies directed to gpnmb and uses thereof |
| 02/22/2007 | WO2006069202A3 Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies |
| 02/22/2007 | WO2006036278A3 THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
| 02/22/2007 | WO2006028967A3 Regulation of oncogenes by micrornas |
| 02/22/2007 | WO2006002119A3 Kinase inhibitors for treating cancers |
| 02/22/2007 | WO2005121338A9 Anti-perp antibody |
| 02/22/2007 | WO2005105113A3 Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine |
| 02/22/2007 | US20070043206 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/22/2007 | US20070043114 Nerve regeneration promoters |
| 02/22/2007 | US20070043095 have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties |
| 02/22/2007 | US20070043079 Heterocyclic compound containing nitrogen atom and use thereof |
| 02/22/2007 | US20070043078 Angiogenesis inhibitor |
| 02/22/2007 | US20070043067 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups |
| 02/22/2007 | US20070043051 Methods and compositions of novel triazine compounds |
| 02/22/2007 | US20070043048 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents |
| 02/22/2007 | US20070043044 such as 2-Amino-4-phenyl-thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide; veterinary medicine; anticancer agents |
| 02/22/2007 | US20070043040 Inhibitors of akt (protein kinase b) |
| 02/22/2007 | US20070043010 Quinazoline derivatives |
| 02/22/2007 | US20070043009 Quinazoline derivatives as tyrosine kinase inhibitors |
| 02/22/2007 | US20070043005 Treatment of hyperproliferative diseases using high doses of active vitamin d |
| 02/22/2007 | US20070042999 Phosphate derivatives of pharmaceutical products |
| 02/22/2007 | US20070042997 Medicament for treatment of dermal pigmentation |
| 02/22/2007 | US20070042992 Inulin products with improved nutritional properties |
| 02/22/2007 | US20070042975 Novel indolopyrrolocarbazole derivative with antitumor activity |
| 02/22/2007 | US20070042971 Crystalline compound of 4'-demethyl-4'-phosphate-2", 3"-bispentafluorophenoxy-acetyl-4", 6"-ethylidene-beta-d-epipodophyllotoxin glucoside either in its free form or solvated with ethanol |
| 02/22/2007 | US20070042965 Crystallized structure of type IV collagen NC1 domain hexamer |
| 02/22/2007 | US20070042947 Agents for preventing and/or treating uppper digestive tract disorders |
| 02/22/2007 | US20070042941 Galectin 9-inducing factors |
| 02/22/2007 | US20070042447 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) |
| 02/22/2007 | US20070042439 Porphyrin compound containing biotinyl group and use thereof |
| 02/22/2007 | US20070042432 Method of diagnosis and treatment |
| 02/22/2007 | US20070042416 Dendritic Enriched Secreted Lymphocyte Activation Molecule |
| 02/22/2007 | US20070042040 Methods and compositions using gonadotropin hormone releasing hormone |
| 02/22/2007 | US20070041985 Modulation of the poliovirus receptor function |
| 02/22/2007 | US20070041968 Methods of inducing an immune response |
| 02/22/2007 | US20070041964 WISP polypeptides and nucleic acids encoding same |
| 02/22/2007 | US20070041956 Vaccine immunotherapy for immune suppressed patients |
| 02/22/2007 | US20070041941 Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same |
| 02/22/2007 | US20070041939 Modified cytokines for use in cancer therapy |
| 02/22/2007 | US20070041938 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 02/22/2007 | US20070041908 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 02/22/2007 | US20070041900 Method and device for radiotherapy |
| 02/22/2007 | DE69530936C5 Boronsäure-und-esterverbindungen, deren systhese und verwendungen Boronic acid and ester compounds whose systhese and uses |
| 02/22/2007 | DE202006018834U1 Zusammensetzung mit einem Getreidemahlerzeugnis Composition with a grain milling product |
| 02/22/2007 | DE102006005221B3 Use of 1-arylisochroman derivative having cell proliferation inhibitory activity to treat or prevent cancer such as glioblastoma or glioma |
| 02/22/2007 | DE102005039579A1 Composition, useful e.g. for prophylaxis and treatment of cancer disease, comprises a nano particle, a therapeutic substance, a carrier, auxiliary material and/or solvent |
| 02/22/2007 | DE10101522B4 Neue pharmazeutische Verwendung einer Kombination aus Ascorbat und mindestens einem Fibrinolysehemmer New pharmaceutical use a combination of ascorbate and at least one Fibrinolysehemmer |
| 02/22/2007 | CA2619769A1 Scavenger of in vivo harmful reactive oxygen species and/or free radicals |
| 02/22/2007 | CA2619763A1 Fas binding antibodies |
| 02/22/2007 | CA2619459A1 Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| 02/22/2007 | CA2619276A1 Pentacyclic kinase inhibitors |
| 02/22/2007 | CA2619223A1 Fluoro substituted 2-oxo azepan derivatives |
| 02/22/2007 | CA2619039A1 1-acyldihydropyrazole derivatives |
| 02/22/2007 | CA2619005A1 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| 02/22/2007 | CA2618747A1 Substituted imidazole compounds as ksp inhibitors |
| 02/22/2007 | CA2618724A1 Imidazole compounds that modulate hsp90 activity |
| 02/22/2007 | CA2618653A1 Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder |
| 02/22/2007 | CA2618513A1 Unsaturated heterocyclic derivatives |
| 02/22/2007 | CA2618377A1 Pyrazole compounds that modulate hsp90 activity |
| 02/22/2007 | CA2617979A1 Combination of a pyrimydlaminobenzamide tyrosine kinase inhibitor and a histone deacetylase inhibitor |
| 02/22/2007 | CA2617642A1 Treatment of proliferative disorders |
| 02/22/2007 | CA2617359A1 Compounds and compositions as protein kinase inhibitors |
| 02/22/2007 | CA2556473A1 Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith |
| 02/21/2007 | EP1754788A2 Prostate-specific membrane antigen and uses thereof |
| 02/21/2007 | EP1754714A1 cyclic peptide derivatives as inhibitors of integrin alpha v beta 6 |
| 02/21/2007 | EP1754712A2 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 02/21/2007 | EP1754710A2 2'-Fluoroncucleosides |
| 02/21/2007 | EP1754707A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 02/21/2007 | EP1754706A1 SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON |
| 02/21/2007 | EP1754703A2 N-Heterocyclic derivatives as nos inhibitors |
| 02/21/2007 | EP1754488A1 Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| 02/21/2007 | EP1754484A1 Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes |
| 02/21/2007 | EP1754473A1 Antitumor agent |
| 02/21/2007 | EP1753858A2 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins |
| 02/21/2007 | EP1753750A1 Thiophene heteroaryl amines |
| 02/21/2007 | EP1753744A1 Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
| 02/21/2007 | EP1753732A1 Phenyl-sulfamates as aromatase inhibitors |
| 02/21/2007 | EP1753727A1 Novel cis-imidazolines |
| 02/21/2007 | EP1753723A1 Substituted quinoline derivatives as mitotic kinesin inhibitors |
| 02/21/2007 | EP1753512A2 Tetrahydropyridothiophenes |
| 02/21/2007 | EP1753463A2 Antibody drug conjugates and methods |
| 02/21/2007 | EP1753425A1 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer |
| 02/21/2007 | EP1753420A1 Indole derivatives useful for treating resistance to antitumour agents |
| 02/21/2007 | EP1578369A4 Screening strategy for anticancer drugs |
| 02/21/2007 | EP1529047B1 New purine derivatives |
| 02/21/2007 | EP1519726B1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |